Bhatia S, Nghiem P, Veeranki SP, Vanegas A, Lachance K, Tachiki L, Chiu K, Boller E, Bharmal M. Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study. J Immunother Cancer. 2022 Aug;10(8):e004904. doi: 10.1136/jitc-2022-004904
Bhatia S, Nghiem P, Veeranki SP, Vanegas A, Lachance K, Tachiki L, Chiu K, Boller E, Bharmal M. Real-world clinical outcomes among patients with advanced Merkel cell carcinoma treated with avelumab in academic medical centers in the United States. Poster presented at the SITC 2021 36th Anniversary Annual Meeting; November 9, 2021. Washington, DC. [abstract] J Immunother Cancer. 2021 Nov; 9(Suppl 2):A658.
Smith VK, Evans MF, Banzhaf HS, Poulos C. Can weak substitution be rehabilitated? Environ Resour Econ (Dordr). 2010 Feb 1;45(2):203-21.
Mansfield CA. Despairing over disparities: an empirical analysis of the relationship between willingness-to-pay and willingness-to-accept. Environ Resour Econ (Dordr). 1999;13(2):219-34.